This announcement is a separate document:
山東新華製藥股份:海外監管公告-關於全資子公司頭孢克洛膠囊通過仿製藥一致性評價的公告
SHANDONG XINHUA: Overseas Regulatory Announcement-Announcement on Cefaclor Capsules of Wholly-owned Subsidiary Passing the Generics Consistency Evaluation
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.